Neuropathic pain in patients with post-COVID-19

ÇOMRUK, EMİNE BURCU; Büyükavcı, Raikan; ÇOMRUK, Erol; aktürk, semra; Ersoy, Yuksel

doi:10.14744/nci.2022.31932

Neuropathic pain in patients with post-COVID-19

Emine Burcu ÇOMRUK, (İnönü Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Malatya, Türkiye)

Raikan BÜYÜKAVCI, (İnönü Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Malatya, Türkiye)

Erol ÇOMRUK, (İnönü Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, Malatya, Türkiye)

Semra AKTÜRK, (İnönü Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Malatya, Türkiye)

Yüksel ERSOY (İnönü Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Malatya, Türkiye)

İstanbul Kuzey Klinikleri

2 1

Yıl: 2023 Cilt: 10 Sayı: 3 Sayfa Aralığı: 359 - 366 Metin Dili: İngilizce DOI: 10.14744/nci.2022.31932 İndeks Tarihi: 27-07-2023

Neuropathic pain in patients with post-COVID-19

Öz:

OBJECTIVE: In this study, we aimed to determine the continuing pain during the post-COVID-19 period the frequency of neuropathic pain in these patients, and the factors affecting the frequency. METHODS: A total of 209 participants were included in the study who had COVID-19 disease (PCR-positive) aged 18–75 years. The demographic characteristics and COVID-19 severity data were recorded by questioning the patients. The musculoskeletal pain was also assessed using Visual Analog Scale (VAS) and the extended Nordic musculoskeletal system questionnaire (NMQ-E). In addition, the neuropathic components of pain were evaluated using the Leeds Assessment of neuropathic symptoms and Signs (LANSS) pain scale and the Pain-DETECT questionnaire (PDQ). RESULTS: The mean time elapsed since COVID-19 was 5.76±2.95 months (min, 1; max, 12). Six patients (2.9%) had neuropathic pain according to the LANSS score, and 12 patients (5.7%) according to the PDQ score. The NMQ-E indicated that the most pain was detected in the back (20.1%), low back (15.3%), and knee (11.5%) regions during the post-COVID-19 period. According to both neuropathic pain scales; low back pain (p=0.001/0.001) and knee pain (p=0.001/0.01) were more common in patients with PDQ/LANSS neuropathic pain. Logistic regression analysis showed that there were significant associations between neuropathic pain and acute COVID-19 VAS score. CONCLUSION: This study demonstrated that musculoskeletal pain was prominent mostly in the back, low back, and knee during the post-COVID-19 period. The incidence of neuropathic pain was 2.9%–5.7% depending on the evaluation parameters. Neuropathic pain is a finding that should be considered during the post-COVID-19 period.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/?adgroupsurvey={ adgroupsurvey}&gclid=CjwKCAjw9pGjBhB-EiwAa5jl3GpDYOFs_ uDb-UbORWo9TVeJ-3t7XFQleB23IL_LJDhYQBRQqbGb- 3BoC2OUQAvD_BwE. Accessed May 17, 2023.
2. Wu F, Zhao S, Yu B, Chen, YM, Wang, W, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–9.
3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536–44.
4. Attal N, Martinez V, Bouhassira D. Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Pain Rep 2021;27:6:e884.
5. Odozor CU, Roles K, Burk C, Kannampallil T., Clifford DB, Piccirillo JF, et al. Cohort study protocol to characterize the incidence and severity of neuropathic pain in patients with severe acute respiratory syndrome coronavirus 2 infection. Pain Rep 2021;20:6:e925.
6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683–90.
7. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020;181:1016–35.
8. Correia AO, Feitosa PWG, Moreira JLS, Nogueira S, Fonseca RB, Nobre M, et al. Neurological manifestations of COVID-19 and other coronaviruses: a systematic review. Neurol Psychiatry Brain Res 2020;37:27–32.
9. Shiers S, Ray PR, Wangzhou A, Sankaranarayanan I, Tatsui CE, Rhines LD, et al. ACE2 and SCARF expression in human dorsal root ganglion nociceptors: implications for SARS-CoV-2 virus neurological effects. Pain 2020;161:2494–501.
10. McWilliam M, Samuel M, Alkufri FH. Neuropathic pain post- COVID-19: a case report. BMJ Case Rep 2021;22:14:e243459.
11. Aksan F, Nelson EA, Swedish KA. A COVID-19 patient with intense burning pain. J Neurovirol 2020;26:800–1.
12. Jena D, Sahoo J, Barman A, Dalai A, Patel S. Neuropathic pain in hospitalized patients with COVID-19: a prospective case series. Arch Rehabil Res Clin Transl 2022;4:100188.
13. Crawford JO. The Nordic Musculoskeletal Questionnaire. Occup Med 2007;57:300–1.
14. Alkan H, Ardic F, Erdogan C, Sahin, F, Sarsan A, Findikoglu G, et al. Turkish version of the painDETECT questionnaire in the assessment of neuropathic pain: a validity and reliability study. Pain Med 2013;14:1933–43.
15. Yucel A, Senocak M, Kocasoy Orhan E, Cimen A, Ertas M. Results of the leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. J Pain 2004;5:427–32.
16. Brizzi KT, Lyons JL. Peripheral nervous system manifestations of infectious diseases. Neurohospitalist 2014;4:230–40.
17. Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015;23:468–78.
18. Pennisi M, Lanza G, Falzone L, Fisicaro F, Ferri R, Bella R. SARSCoV- 2 and the nervous system: from clinical features to molecular mechanisms. Int J Mol Sci 2020;21:5475.
19. Baptista AF, Baltar A, Okano AH, Moreira A, Campos A, Fernandes AM, et al. Applications of non-invasive neuromodulation for the management of disorders related to COVID-19. Front Neurol 2020;11:573718.
20. Weng LM, Su X, Wang XQ. Pain symptoms in patients with coronavirus disease (COVID-19): a literature review. J Pain Res 2021;14:147– 59.
21. Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife 2020;9:e59177.
22. Ciaffi J, Meliconi R, Ruscitti P, Berardicurti O, Giacomelli R, Ursini F. Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC Rheumatol 2020;4:65.
23. Xie H, Lu F, Liu W, Wang E, Wang L, Zhong M. Remimazolam alleviates neuropathic pain via regulating bradykinin receptor B1 and autophagy. J Pharm Pharmacol 2021;73:1643–51.
24. Trujillo CA, Negraes PD, Schwindt TT, Lameu C, Carromeu C, Muotri AR, et al. Kinin-B2 receptor activity determines the differentiation fate of neural stem cells. J Biol Chem 2012;287:44046–61.
25. Lu DY, Leung YM, Huang SM, Wong KL. Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. J Cell Biochem 2010;110:141–50.
26. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez- Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 2020;95:e1060–70.
27. Özdağ Acarli AN, Samanci B, Ekizoğlu E, Çakar A, Şirin NG, Gündüz T, et al. Coronavirus disease 2019 (COVID-19) from the point of view of neurologists: observation of neurological findings and symptoms during the combat against a pandemic. Noro Psychiatrist Ars 2020;57:154–9.
28. Oguz-Akarsu E, Gullu G, Kilic E, Dinç Y, Ursavas A, Yilmaz E, et al. Insight into pain syndromes in acute phase of mild-to-moderate COVID-19: frequency, clinical characteristics, and associated factors. Eur J Pain 2022;26:492–504.
29. Fernández-de-Las-Peñas C, de-la-Llave-Rincón AI, Ortega-Santiago R, Ambite-Quesada S, Gómez-Mayordomo V, Cuadrado ML, et al. Prevalence and risk factors of musculoskeletal pain symptoms as longterm post-COVID sequelae in hospitalized COVID-19 survivors: a multicenter study. Pain 2022;163:e989–96.
30. Yang CW, Fuh JL. Screening tools for neuropathic pain. J Chin Med Assoc 2018;81:1–3.
31. Van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155:654–62.

APA	ÇOMRUK E, Büyükavcı R, ÇOMRUK E, aktürk s, Ersoy Y (2023). Neuropathic pain in patients with post-COVID-19. , 359 - 366. 10.14744/nci.2022.31932
Chicago	ÇOMRUK EMİNE BURCU,Büyükavcı Raikan,ÇOMRUK Erol,aktürk semra,Ersoy Yuksel Neuropathic pain in patients with post-COVID-19. (2023): 359 - 366. 10.14744/nci.2022.31932
MLA	ÇOMRUK EMİNE BURCU,Büyükavcı Raikan,ÇOMRUK Erol,aktürk semra,Ersoy Yuksel Neuropathic pain in patients with post-COVID-19. , 2023, ss.359 - 366. 10.14744/nci.2022.31932
AMA	ÇOMRUK E,Büyükavcı R,ÇOMRUK E,aktürk s,Ersoy Y Neuropathic pain in patients with post-COVID-19. . 2023; 359 - 366. 10.14744/nci.2022.31932
Vancouver	ÇOMRUK E,Büyükavcı R,ÇOMRUK E,aktürk s,Ersoy Y Neuropathic pain in patients with post-COVID-19. . 2023; 359 - 366. 10.14744/nci.2022.31932
IEEE	ÇOMRUK E,Büyükavcı R,ÇOMRUK E,aktürk s,Ersoy Y "Neuropathic pain in patients with post-COVID-19." , ss.359 - 366, 2023. 10.14744/nci.2022.31932
ISNAD	ÇOMRUK, EMİNE BURCU vd. "Neuropathic pain in patients with post-COVID-19". (2023), 359-366. https://doi.org/10.14744/nci.2022.31932

APA	ÇOMRUK E, Büyükavcı R, ÇOMRUK E, aktürk s, Ersoy Y (2023). Neuropathic pain in patients with post-COVID-19. İstanbul Kuzey Klinikleri, 10(3), 359 - 366. 10.14744/nci.2022.31932
Chicago	ÇOMRUK EMİNE BURCU,Büyükavcı Raikan,ÇOMRUK Erol,aktürk semra,Ersoy Yuksel Neuropathic pain in patients with post-COVID-19. İstanbul Kuzey Klinikleri 10, no.3 (2023): 359 - 366. 10.14744/nci.2022.31932
MLA	ÇOMRUK EMİNE BURCU,Büyükavcı Raikan,ÇOMRUK Erol,aktürk semra,Ersoy Yuksel Neuropathic pain in patients with post-COVID-19. İstanbul Kuzey Klinikleri, vol.10, no.3, 2023, ss.359 - 366. 10.14744/nci.2022.31932
AMA	ÇOMRUK E,Büyükavcı R,ÇOMRUK E,aktürk s,Ersoy Y Neuropathic pain in patients with post-COVID-19. İstanbul Kuzey Klinikleri. 2023; 10(3): 359 - 366. 10.14744/nci.2022.31932
Vancouver	ÇOMRUK E,Büyükavcı R,ÇOMRUK E,aktürk s,Ersoy Y Neuropathic pain in patients with post-COVID-19. İstanbul Kuzey Klinikleri. 2023; 10(3): 359 - 366. 10.14744/nci.2022.31932
IEEE	ÇOMRUK E,Büyükavcı R,ÇOMRUK E,aktürk s,Ersoy Y "Neuropathic pain in patients with post-COVID-19." İstanbul Kuzey Klinikleri, 10, ss.359 - 366, 2023. 10.14744/nci.2022.31932
ISNAD	ÇOMRUK, EMİNE BURCU vd. "Neuropathic pain in patients with post-COVID-19". İstanbul Kuzey Klinikleri 10/3 (2023), 359-366. https://doi.org/10.14744/nci.2022.31932